Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Cancer Res. 2012 Feb 15;72(4):876-86. doi: 10.1158/0008-5472.CAN-11-1792. Epub 2011 Dec 15.
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of cells that accumulate during tumor formation, facilitate immune escape, and enable tumor progression. MDSCs are important contributors to the development of an immunosuppressive tumor microenvironment that blocks the action of cytotoxic antitumor T effector cells. Heterogeneity in these cells poses a significant barrier to studying the in vivo contributions of individual MDSC subtypes. Herein, we show that granulocyte-macrophage colony stimulating factor, a cytokine critical for the numeric and functional development of MDSC populations, promotes expansion of a monocyte-derived MDSC population characterized by expression of CD11b and the chemokine receptor CCR2. Using a toxin-mediated ablation strategy to target CCR2-expressing cells, we show that these monocytic MDSCs regulate entry of activated CD8 T cells into the tumor site, thereby limiting the efficacy of immunotherapy. Our results argue that therapeutic targeting of monocytic MDSCs would enhance outcomes in immunotherapy.
髓系来源的抑制细胞 (MDSC) 是一种在肿瘤形成过程中积累的异质性细胞群体,它促进免疫逃逸,并使肿瘤进展。MDSC 是形成抑制抗肿瘤 T 效应细胞作用的免疫抑制性肿瘤微环境的重要贡献者。这些细胞的异质性对研究单个 MDSC 亚型在体内的贡献构成了重大障碍。在此,我们表明粒细胞-巨噬细胞集落刺激因子(一种对 MDSC 群体的数量和功能发育至关重要的细胞因子)促进了表达 CD11b 和趋化因子受体 CCR2 的单核细胞来源的 MDSC 群体的扩增。我们使用毒素介导的消融策略来靶向表达 CCR2 的细胞,结果表明这些单核细胞 MDSC 调节了激活的 CD8 T 细胞进入肿瘤部位的进入,从而限制了免疫疗法的效果。我们的结果表明,针对单核细胞 MDSC 的治疗性靶向可能会增强免疫疗法的效果。